Guggenheim analyst Vamil Divan raised the firm’s price target on Travere Therapeutics (TVTX) to $47 from $45 and keeps a Buy rating on the shares. The company’s announcement this week that they have reached alignment with the FDA on filing a Filspari sNDA in focal segmental glomerulosclerosis makes the firm “increasingly optimistic” on an FSGS approval later this year, so it increased its view of the probability of success to 85% from 75%, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics: Strong Buy Rating Driven by Filspari’s $1 Billion Market Potential in FSGS
- Travere Therapeutics price target raised to $32 from $27 at Scotiabank
- Travere Therapeutics price target raised to $45 from $22 at Canaccord
- Coca-Cola reports Q4 beat, Elliott discloses Phillips 66 stake: Morning Buzz
- Wells bullish on Travere Therapeutics, sees 30% of upside on submission plans